Clinical Trial Pipeline Tracker

Research evidence excerpt

Not for redistribution without written consent of Morgan Stanley

M

Update

August 7, 2026 08:01 PM GMT

Biopharma | North America

Morgan Stanley & Co. LLC

Terence C Flynn, Ph.D.

Equity Analyst

Clinical Trial Pipeline Tracker

Sean Laaman, Ph.D.

Equity Analyst

We highlight key changes to the clinical trials of companies

under coverage occurring from 7/29-8/5. See inside for a full list

of changes.

M

New Trials ( Exhibit 1 )

Equity Analyst

(STEAP1xCD3 BiTE) in Participants With Metastatic Castrate Resistant

Equity Analyst

Tetraxetan

Research Associate

DOK7-,MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS)

• Beone Medicines: The company has initiated a Ph1 First-in-Human Study

(NCT07746141) Investigating BG-85738 Alone or in Combination With Other

Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors

With Rat Sarcoma Virus (RAS) Mutations

• Cullinan: The company has initiated a Ph1b/2a Study (NCT07738822) of

Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA

• Johnson & Johnson: The company has initiated a Ph3 Study (NCT07740486)

of Comparing Treatment With Teclistamab and Talquetamab Versus

Chris Yu, J.D., Ph.D.

Alexander Yevdokimov, Ph.D.

Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With

Maxwell Skor

Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide

• Argenx: The company has initiated a Ph3 Trial (NCT07746089) to Assess

Judah C. Frommer, CFA

• Amgen: The company has initiated a Ph2 Trial (NCT07737925) of Xaluritamig

Michael E Ulz

Connor M Massari

Equity Analyst

Michael H Riad, Ph.D.

Research Associate

Katherine Sun

Research Associate

Hailey Horowitz

Research Associate

Rohit Bhasin

Research Associate

Daratumumab and Lenalidomide in Patients With Multiple Myeloma After

Selena Zhang

Stem Cell Transplant Who Still Have Detectable Disease

Research Associate

Nicholas D Japhet

Terminated ( Exhibit 2 )

Research Associate

• N/A

Avraham Novick

Research Associate

Recruiting ( Exhibit 3 )

Parth Patel

Research Associate

• Abbvie: The company is recruiting in a Ph1 study (NCT07365241) to Evaluate

Adverse Events and Change in Disease Activity of Intravenous ABBV-706

…